Phase I/II study to evaluate combination rucaparib and sacituzumab govitecan in patients with metastatic triple-negative breast cancer and metastatic urothelial cancer
Phase of Trial: Phase I/II
Latest Information Update: 26 Feb 2019
Price : $35 *
At a glance
- Drugs Rucaparib (Primary) ; Sacituzumab govitecan (Primary)
- Indications Advanced breast cancer; Ovarian cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Clovis Oncology
- 26 Feb 2019 According to a Clovis Oncology media release, the enrolment is expected to begin in 2019.
- 08 Jun 2018 New trial record
- 03 Jun 2018 According to a Clovis Oncology media release, Clovis Oncology and Immunomedics announce planned clinical collaboration for this study.